Axsome Therapeutics (AXSM) Debt/EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 0.29 | 0.61 | 0.89 | 0.45 | 0.49 | 0.51 | |||
| Changes by years, y/y, % | -78% | +105% | +47% | -49% | +8% | -18.3% | |||
Axsome Therapeutics. Debt/EBITDA
Axsome Therapeutics. Debt/EBITDA, changes, %
Axsome Therapeutics (AXSM) Debt/EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| Debt/EBITDA | 0.34 | 0.38 | 0.50 | 0.49 | 0.49 | 0.51 | ||
| Changes by years, y/y, % | -31% | -10% | +11% | +9% | +44% | |||
| Changes by quarters, q/q, % | -24% | +10% | +34% | -2% | +1% | |||